At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
doxercalciferoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease
In Brief
A Phase 4 clinical trial evaluating doxercalciferol for Hyperparathyroidism, Secondary and Kidney Failure, Chronic. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Patients with chronic kidney disease and end stage renal disease have greater cardiovascular risk than the general population. Vitamin D analogues have been shown in observational studies to have mortality benefit for these patients. This study is designed to investigate doxercalciferol's effect on the vasculature (i.e. endothelial cell function) as a possible mechanism to explain the mortality benefit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGenzyme, a Sanofi Company
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionAug 2012
TodayJul 2026
First PostedSep 12, 2007
Enrollment StartSep 1, 2007
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 18.8 years ago
Interventions
doxercalciferoldrug